Navigation Links
PDX in Medical News

Emdeon Acquires eRx Network, LLC

...ition, Emdeon, PDX, Inc. and eRx entered into a long term extension and expansion of the strategic relationship that has been in place between eRx and pdx since eRx's founding. "We are delighted to combine our pharmacy business with eRx," said George Lazenby, chief executive officer of Emdeon. "Th...

PDX-Rx.com Works With Microsoft HealthVault to Make Prescription Data Available to Patients

...TM) FORT WORTH, Texas, June 9 /PRNewswire/ -- pdx and Rx.com have entered into a strategic agreement...ients' prescription history into HealthVault. Each pdx pharmacy client will have their own independent relationship with Microsoft, while pdx serves to technically integrate the pharmacy's dat...

Albertson's, LLC Selects PDX-NHIN-Rx.com to Provide Complete Pharmacy Management Solution

...- Boise, Idaho-based Albertson's, LLC has selected pdx and affiliates Rx.com and NHIN as its turnkey part...ess was pharmacy software development. In the end, pdx best met our needs." George Owens, Senior Vice President at pdx said, "We are especially pleased to have Albertson...

New lymphoma therapies targets diverse and difficult cancer

...ne at Columbia University College of Physicians and Surgeons. One of the most promising new therapies developed at NewYork-Presbyterian/Columbia is pdx (pralatrexate) for T-cell lymphoma -- among the most fatal forms of the disease. The drug is uniquely designed to camouflage itself as a folic acid, w...

Allos Therapeutics Appoints Bruce K. Bennett as Vice President, Manufacturing

... agreement reached with the U.S. Food and Drug Administration under its special protocol assessment, or SPA process. The Company is also investigating pdx in patients with non-small cell lung cancer and a range of lymphoma sub-types. The Company's other product candidate is RH1, a targeted chemotherapeut...

Allos Therapeutics to Present at the 2007 RBC Capital Markets Healthcare Conference

... agreement reached with the U.S. Food and Drug Administration under its special protocol assessment, or SPA process. The Company is also investigating pdx in patients with non-small cell lung cancer and a range of lymphoma sub-types. The Company's other product candidate is RH1, a targeted chemotherapeut...

PDX-NHIN and Health Market Science to Jointly Market Standardized Prescriber File

...ave entered into an agreement to jointly market to pdx Pharmacy System users the HMS Prescriber Master Fi... provided through NHIN in a manner that will allow pdx customers to access this data using PDX Distributed Processing, a feature of the pdx Pharmacy System that allows access to databases in...

Allos Therapeutics Reports Third Quarter 2007 Financial Results

...September 30, 2007 were $63.4 million. "With five pdx trials ongoing and two additional studies schedule...ke important progress advancing the development of pdx in hematologic malignancies and solid tumors," sta...er of Allos. "PROPEL, our pivotal Phase 2 trial of pdx in patients with relapsed or refractory peripheral...

Allos Therapeutics to Present at the 2007 Acumen BioFin Rodman & Renshaw Conference

... agreement reached with the U.S. Food and Drug Administration under its special protocol assessment, or SPA process. The Company is also investigating pdx in patients with non-small cell lung cancer and a range of other lymphoma sub-types. The Company's other product candidate is RH1, a targeted chemothe...

HealthShares(TM) Announces Quarterly Rebalancing of HealthShares(TM) Indexes

...et, Inc. HNT 311854162.6 Davita Inc DVA 230769230.8 Pediatrix Medical Group pdx 173618639.9 Humana Inc. HUM 138944124.3 Healthsouth Corp HLS 525336900.2 Che...
PDX in Medical Technology

Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma

WESTMINSTER, Colo., Dec. 27 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. (Nasdaq: ALTH ) today announced that an independent Data Monitoring Committee (DMC) has completed the pre-specified 65-patient safety review of data from the Company's pivotal Phase 2 PROPEL trial of PDX (pralatrex...

Interim Response and Safety Analyses Support Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma

PROPEL Enrollment Ahead of Schedule with Completion Expected Q2 2008 WESTMINSTER, Colo., Sept. 24 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. (Nasdaq: ALTH ) today announced the completion of pre-planned interim analyses of patient response and safety data from the Company's pivotal ...

Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma

WESTMINSTER, Colo., Aug. 15 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. (Nasdaq: ALTH ) today announced the initiation of patient enrollment in a Phase 1, open-label, multi-center study of the Company's novel antifolate PDX (pralatrexate) with vitamin B12 and folic acid supplementation...

Allos Therapeutics' PDX Granted Orphan Medicinal Product Designation by the European Commission

WESTMINSTER, Colo., April 19, 2007 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. today announced that the Commission of the European Communities, with a favorable opinion of the Committee for Orphan Medicinal Products of the European Medicines Agency (EMEA), has granted orphan drug designatio...

Allos Therapeutics Initiates Study of RH1 in Patients with Advanced Solid Tumors or non-Hodgkin's Lymphoma

... agreement reached with the U.S. Food and Drug Administration under its special protocol assessment, or SPA process. The Company is also investigating pdx in patients with non-small cell lung cancer and a range of lymphoma sub-types. The Company's other product candidate is RH1, a targeted chemotherapeut...

ApoCell's Cancer Predictive Index Helps Oncologists Select the Most Effective Targeted Drug Therapy

...t. ApoCell has developed an analytical tool, the pdx Index(TM) (Pharmaco-Diagnostic Index), which indic...President and CEO comments, "We have developed the pdx Index(TM) methodology to give drug developers, cli...e same cancer drug therapy. By knowing a patient's pdx Index(TM) score ahead of time, the physician can p...

Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer

...faproxyn and focus on advancing the development of pdx (pralatrexate), its novel antifolate currently und...rmination in advancing the clinical development of pdx and RH1, and look forward to providing future upda...icer. "We expect to provide the next update on our pdx PROPEL study later this year following completion ...
PDX in Biological News

A molecular switch turns on the flame in 'nature's blowtorch'

...orientation around the peptide bond, and moves the P450 from the form in which substrate binds to the active form. After the reaction is finished, the pdx falls off, the P450 moves back to the unactivated state, and the oxidized products are free to leave. After another substrate molecule and oxygen m...
PDX in Biological Technology

Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference

MTD in NSCLC Identified; Phase 2 Study Planned WESTMINSTER, Colo., Oct. 25 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. (Nasdaq: ALTH ), a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer, ...

Allos Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference

... agreement reached with the U.S. Food and Drug Administration under its special protocol assessment, or SPA process. The Company is also investigating pdx in patients with non-small cell lung cancer and a range of lymphoma sub-types. The Company's other product candidate is RH1, a targeted chemotherapeut...

Allos Therapeutics to Present at the 2007 JMP Securities Healthcare Focus Conference

... agreement reached with the U.S. Food and Drug Administration under its special protocol assessment, or SPA process. The Company is also investigating pdx in patients with non-small cell lung cancer and a range of other lymphoma sub-types. The Company's other product candidate is RH1, a targeted chemothe...

Allos Therapeutics to Present at the 2007 UBS Global Life Sciences Conference

...ntly under evaluation in a pivotal Phase 2 trial in patients with relapsed or refractory peripheral T-cell lymphoma. The Company is also investigating pdx in patients with non-small cell lung cancer and a range of other lymphoma sub-types. The Company's other product candidate is RH1, a targeted chemothe...

Allos Therapeutics to Present at the Bear Stearns 20th Annual Healthcare Conference

...ntly under evaluation in a pivotal Phase 2 trial in patients with relapsed or refractory peripheral T-cell lymphoma. The Company is also investigating pdx in patients with non-small cell lung cancer and a range of other lymphoma sub-types. The Company's other product candidate is RH1, a targeted chemothe...
Other Tags
(Date:7/11/2014)... Rochester, NY (PRWEB) July 11, 2014 ... Surgery ’s own, Dr. William Koenig, has topped a ... his peers, he has performed over 400 successful procedures ... , Dr. Koenig is well known across the country ... His exceptional safety record has long been the foundation ...
(Date:7/11/2014)... people with sex addiction, pornography affects the brain in ... addicts as they consume drugs, a new study finds. ... patients who have compulsive sexual behavior and healthy volunteers. ... Dr. Valerie Voon, of the University of Cambridge in ... research involved 19 men with sex addiction and a ...
(Date:7/11/2014)... July 11, 2014 (HealthDay News) -- U.S. health officials ... were exposed to live anthrax during a safety mishap ... Control and Prevention officials have announced a moratorium on ... high-level government labs. In a report issued Friday, ... to make sure a similar incident doesn,t occur again. ...
(Date:7/11/2014)... The report “Probiotics Market by Products (Functional Foods, ... Therapeutic, Preventive Health Care) & Ingredients (Lactobacilli, Bifidobacteria, ... ” defines and segments the global probiotics market ... value of probiotic products and ingredients. The report ... the global market with an analysis of trends, ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 According to ... & Application Market by Communication Technology (ZigBee, Z-Wave, Bluetooth, ... Electronics, Industrial, Automotive & Transportation, Agriculture) & Geography - ... value of Internet of Things market was worth $1029.5 ... Billion by 2020, at an estimated CAGR of 4.08% ...
Breaking Medicine News(10 mins):Health News:Rochester Surgeon Hits Milestone with Keller Funnel 2Health News:Brains of Sex Addicts May Be Wired Like Those of Drug Addicts, Study Finds 2Health News:CDC Issues Tough Report on Anthrax Scare 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 3Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 4Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 5Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 4
(Date:7/11/2014)... marginal division of the striatum is also involved ... degree of substance P in the striatal marginal ... and his team, College of Biophotonics, South China ... substance P receptor, neurokinin 1 was highly expressed ... normal rats. Unilateral or bilateral injection of an ...
(Date:7/11/2014)... 2014 Research and Markets has ... Market - Industry Analysis Size Share Growth Trends and ... http://photos.prnewswire.com/prnh/20130307/600769 The ... a need for high level security in both private ... such as username and passwords, tokens etc. are vulnerable ...
(Date:7/10/2014)... and other major cities in New Mexico, nearly every ... wastewater rather than precious potable water supplies. Across the ... all golf courses receive treated effluent. Reusing the effluent ... golf courses and homeowners alike fertilize their lawns during ... nitrate. A New Mexico State University turfgrass expert has ...
Breaking Biology News(10 mins):International Biometrics Technology Market - Industry Analysis Size Share Growth Trends and Forecast to 2019 2'Tailored' water -- the latest in lawn care 2
Other Contents